Enjoy complimentary customisation on priority with our Enterprise License!
The global gastric cancer drugs market size is estimated to grow/decline by USD 19.48 billion, at a CAGR of 18.52% between 2024 and 2028. As the prevalence of gastric cancer rises, particularly among the growing geriatric population, there is a concurrent increase in awareness campaigns aimed at educating the public. These campaigns emphasize early detection and symptom awareness to improve patient outcomes. The growing geriatric demographic is particularly vulnerable to gastric cancer, necessitating proactive health education initiatives. By raising awareness about risk factors and promoting regular screenings, healthcare providers aim to mitigate the impact of this disease. Addressing the rising prevalence through targeted educational efforts is crucial in ensuring timely diagnosis and effective treatment options for affected individuals, thereby improving overall public health outcomes.
To learn more about this report, Request Free Sample
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Abbott Laboratories: The company offers a gastric cancer drug called Priunta 440mg Injection.
AbbVie Inc., AROG Pharmaceuticals INC., AstraZeneca Plc, Bayer AG, Biocon Ltd., Blueprint Medicines Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Merck KGaA, Novartis AG, Otsuka Holdings Co. Ltd., Samsung Biologics Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Zydus Lifesciences Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the Injectagble segment will be significant during the forecast period. Drug injection is a method of introducing a drug into the bloodstream by using a hypodermic needle, which is pierced through the skin into the body (muscles or nerves). The market witnesses the presence of various vendors that are developing novel drugs for administration through injectable routes. Most drugs that are being developed in the late stages of the gastric cancer drugs pipeline are biologics. The injectable route remains the most preferred route for biologics, as the administration through the oral route often results in the drug losing its efficacy.
Get a glance at the market contribution of various segments Download PDF Sample
The Injectable segment accounted for USD 7.05 billion in 2018 and showed a gradual increase during the forecast period. These drugs are expected to add significant value to global gastric cancer drugs market growth owing to their high efficacy and demand. The popularity of these drugs for the treatment of various gastric cancer indications is expected to attract a major share of patients to undergo treatment using these drugs during the forecast period. Thus, the introduction of new injectable gastric cancer drugs will drive the growth of the global gastric cancer drugs market during the forecast period.
For more insights about the market share of various regions Download PDF Sample
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. The strong prevalence of gastric cancer in the region and the ease of availability of therapeutics are some major factors that are contributing to the regional gastric cancer drugs market. The American Cancer Societys 2022 estimates include 26,380 new cases and 11,090 deaths from gastric cancer in the US. Similarly, according to the Canadian Cancer Society data in 2023 around 4,100 Canadians were diagnosed with stomach cancer. The increasing geriatric population is another factor contributing to the growth of the market in the region, as gastric cancer most commonly occurs in people over the age of 50 years. Additionally, the availability of advanced healthcare infrastructure and the presence of leading pharmaceutical companies in North America also contribute to the growth of the regional gastric cancer drugs market. These factors have led to the development of innovative drugs that cater to the needs of people with gastric cancer. On the other hand, stringent government regulations regarding the safety and efficacy of drugs may hinder the growth of the market to some extent. However, leading players are investing in research and development to introduce new and effective drugs in the market, which is expected to propel regional gastric cancer drugs market growth during the forecast period.
Gastric carcinoma, including types like gastric adenocarcinoma and gastric neuroendocrine tumors, poses significant challenges in healthcare, often necessitating treatments from pharmaceutical giants. Innovations such as Trastuzumab deruxtecan, Keytruda, and Herceptin are pivotal in targeted therapy, particularly for tumors with specific biomarkers. PD-1 inhibitors like Opdivo offer promising immunotherapy options, while biosimilars from Biocon/Mylan, such as Ogivri and Herzuma from Celltrion/Teva and Samsung Bioepis, provide cost-effective alternatives. Symptoms like nausea, fatigue, bloating, stomach pain, vomiting, and weight loss often accompany gastric carcinoma, prompting early diagnosis based on family history and changes in stomach lining. Advances in identifying biomarkers enable personalized treatment plans, enhancing efficacy and patient outcomes. Continued research and development are crucial in improving therapies and managing the complexities associated with gastric cancer.
The increasing prevalence of gastric cancer is the key factor driving the growth of the market. Over the last few years, there has been a surge in the prevalence of chronic gastrointestinal disorders such as gastric cancer worldwide, leading to increased healthcare costs and a decrease in the quality of life of people with such conditions. One of the primary reasons for the increase in the prevalence of gastric cancer is the change in lifestyles and eating habits. The consumption of processed and fast food, which is high in fat and sugar, has become very common in recent years, leading to conditions such as obesity, which is linked to chronic gastrointestinal disorders, including gastric cancer.
Moreover, a sedentary lifestyle that is devoid of any physical activity or exercise has increasingly become common, as many people have very hectic work schedules that do not leave them with time to exercise. The increase in the prevalence of gastrointestinal cancer has a consequential impact on individual patients and their families. Patients can experience chronic pain, loss of appetite, and reduced quality of life. Thus, the above-mentioned factors are expected to increase the demand for gastric cancer drugs globally, which is expected to propel the growth of the global gastric cancer drugs market during the forecast period.
An increase in the number of drug approvals and drug launches is the primary trend in the market growth. In recent years, there has been a significant increase in the number of approvals by regulatory agencies for gastric cancer drugs. The US FDA has been working closely with pharmaceutical companies to streamline the approval process for these drugs, which has resulted in faster turnaround times, right from submission to approval. In December 2022, AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) were approved by the European Union (EU).
Moreover, it is used as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. In addition, vendors operating in the market have been launching new products for gastric cancer. In March 2022, Samsung Biologics announced the US launch of ONTRUZANT (trastuzumab-dttb) for early and metastatic HER2-overexpressing breast cancer and metastatic gastric cancer. Thus, an increase in the number of drug approvals and launches is expected to fuel the growth of the global gastric cancer drugs market during the forecast period.
High treatment costs of gastric cancer are a major challenge to the growth of the market. Some gastric cancer drugs in the market include Tislelizumab by Novartis, Cyramza injection by Eli Lilly, and Priunta 440 mg Injection by Abbott Laboratories. These drugs are priced very high when compared with traditional chemotherapy drugs due to their ability to target multiple proteins. For instance, Cyramza injection by Eli Lilly costs around USD2,995 to USD3,057 per vial. Hence, most patients, who do not have health insurance or access to patient assistance programs by vendors or governments, cannot afford the treatment using these drugs, which reduces patient adherence and poses a challenge to market growth.
Furthermore, the expected launch of various biologics is likely to increase the costs of treatment during the forecast period. The complex manufacturing process and high R and D costs of biologics often lead to vendors offering these drugs at a high price. These high treatment costs using gastric drugs are expected to be one of the major challenges to global gastric cancer drugs market growth during the forecast period.
The market forecast report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market forecasting and growth strategies.
Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
Gastroesophageal Reflux Disease (GERD) Market: Gastroesophageal Reflux Disease (GERD) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Canada - Size and Forecast
Protein Therapeutics Market: Protein Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast
HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market: HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast
The treatment landscape for gastrointestinal cancers, including gastric carcinoma and gastrointestinal stromal tumors (GIST), is evolving with the introduction of targeted therapies and innovative drugs. Avelumab, HER2 antagonists, and VEGFR antagonists represent advancements in immunotherapy and targeted therapy for cancers like gastroesophageal junction cancer and GIST. Chemotherapeutic agents such as Lonsurf, Fluorouracil, and Capecitabine continue to play crucial roles in treatment regimens, particularly in combination therapies. Specialty pharmacies and hospital pharmacies play integral roles in dispensing medications like Trazimera, Oncoral, and treatments from Daiichi Sankyo Company such as Ayvakit, Gleevec, Stivarga, and Qinlock. These drugs target specific molecular pathways affected by genetic modifications, offering oral options for patients. Platinum-containing chemotherapy remains a cornerstone in managing advanced stages of gastrointestinal cancers, influenced by risk factors like smoking and gastrointestinal reflux disease.
Market Scope |
|
Report Coverage |
Details |
Page number |
168 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 18.52% |
Market growth 2024-2028 |
USD 19.48 billion |
Market structure |
USD Fragmented |
YoY growth 2023-2024(%) |
15.18 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Germany, UK, China, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., AROG Pharmaceuticals INC., AstraZeneca Plc, Bayer AG, Biocon Ltd., Blueprint Medicines Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Merck KGaA, Novartis AG, Otsuka Holdings Co. Ltd., Samsung Biologics Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.